Congratulations to Apexian Pharmaceuticals!
The U.S. Food & Drug Administration has authorized the clinical stage biotechnology company to begin the Phase 1 study of APX3330, its lead compound.
Steve Carchedi, President and Chief Executive Officer of Apexian Pharmaceuticals, said, “We are very excited to have reached this important milestone in the evaluation of APX3330 in patients with cancer and will begin study accrual in the coming months.”
Apexian Pharmaceuticals licenses technology from the Indiana University Research and Technology Corp. A news release about the FDA’s approval to begin the Phase 1 study is available here.
Leave a Reply